Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer.
Adult
Aged
C-Reactive Protein
/ metabolism
Carcinoma, Squamous Cell
/ metabolism
Dexamethasone
/ pharmacology
Fatigue
/ metabolism
Female
Glucocorticoids
/ metabolism
Head and Neck Neoplasms
/ metabolism
Humans
Inflammation
/ metabolism
Interleukin-6
/ metabolism
Longitudinal Studies
Male
Middle Aged
Papillomavirus Infections
/ metabolism
Prospective Studies
Receptors, Glucocorticoid
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Journal
Psychosomatic medicine
ISSN: 1534-7796
Titre abrégé: Psychosom Med
Pays: United States
ID NLM: 0376505
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
18
5
2021
Statut:
ppublish
Résumé
Fatigued cancer patients often have high peripheral inflammation; however, the biological mechanisms of this association remain unclear. We examined whether decreased sensitivity of immune cells to the anti-inflammatory effects of glucocorticoids may contribute to inflammation and fatigue in head and neck cancer (HNC) patients during treatment. HNC patients without distant metastasis and with curative intent (n = 77) were studied 1 week before intensity-modulated radiotherapy (IMRT) and 1 month after IMRT. At each time point, fatigue was measured by the Multidimensional Fatigue Inventory-20 along with plasma inflammation markers and glucocorticoid receptor (GR) sensitivity as determined by in vitro dexamethasone suppression of lipopolysaccharide-induced interleukin 6. Linear regression models were used. In contrast to our hypothesis, GR sensitivity increased during treatment; however, increased fatigue was associated with a lesser increase in GR sensitivity from baseline to 1 month after IMRT (unstandardized estimate = 4.07, p = .02). This effect was more prominent in human papillomavirus-unrelated HNCs (unstandardized estimate = 8.22, p = .002). Lower increases in GR sensitivity were also associated with increased inflammation at 1 month after IMRT as represented by C-reactive protein, interleukin 6, and tumor necrosis factor α. Addition of inflammation markers to models of GR sensitivity predicting fatigue indicated that these inflammation markers were stronger predictors of fatigue than GR sensitivity. Lower increases in GR sensitivity during HNC treatment were significantly predictive of increased fatigue and inflammation markers. Inflammation markers in turn predicted fatigue above and beyond levels of GR sensitivity. Our findings indicate that HNC patients with cancer-related fatigue may exhibit a decreased capacity for glucocorticoids to regulate inflammatory processes, as evidenced by a lower increase in GR sensitivity. Larger studies are necessary to verify the findings.
Identifiants
pubmed: 32515926
doi: 10.1097/PSY.0000000000000816
pii: 00006842-202006000-00007
pmc: PMC7905992
mid: NIHMS1667173
doi:
Substances chimiques
Glucocorticoids
0
Interleukin-6
0
Receptors, Glucocorticoid
0
Tumor Necrosis Factor-alpha
0
Dexamethasone
7S5I7G3JQL
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
508-516Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002381
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR015783
Pays : United States
Organisme : NINR NIH HHS
ID : R00 NR014587
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NINR NIH HHS
ID : K99 NR014587
Pays : United States
Références
Brain Behav Immun. 2011 Nov;25(8):1716-24
pubmed: 21798341
Psychoneuroendocrinology. 2003 Oct;28(7):916-31
pubmed: 12892658
Am J Psychiatry. 2003 Sep;160(9):1554-65
pubmed: 12944327
Mol Endocrinol. 2001 Jul;15(7):1062-76
pubmed: 11435608
Brain Behav Immun. 2011 Jan;25(1):147-50
pubmed: 20854893
Am J Crit Care. 2011 Mar;20(2):146-52
pubmed: 20378777
Brain Behav Immun. 2016 Nov;58:142-151
pubmed: 27263430
Endocr Rev. 1999 Aug;20(4):435-59
pubmed: 10453354
Brain Behav Immun. 2007 May;21(4):413-27
pubmed: 17178209
J Psychosom Res. 2011 Sep;71(3):136-41
pubmed: 21843747
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):5995-9
pubmed: 22474371
Psychol Med. 2017 Jul;47(10):1733-1743
pubmed: 28193310
Cancer. 2018 Aug 1;124(15):3163-3170
pubmed: 29742284
Endocrinology. 1999 Sep;140(9):4359-66
pubmed: 10465310
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
Psychosom Med. 2005 Sep-Oct;67(5):679-87
pubmed: 16204423
J Pain Symptom Manage. 2005 Nov;30(5):433-42
pubmed: 16310617
J Immunol Res. 2018 Nov 12;2018:1061780
pubmed: 30539028
Biol Psychiatry. 2008 Aug 15;64(4):263-5
pubmed: 18675617
Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2636-42
pubmed: 19773451
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Brain Behav Immun. 2009 May;23(4):455-63
pubmed: 19167480
Health Psychol. 2002 Nov;21(6):531-41
pubmed: 12433005
Mol Psychiatry. 2016 Oct;21(10):1358-65
pubmed: 26552591
Psychol Bull. 2007 Jan;133(1):25-45
pubmed: 17201569
Adv Exp Med Biol. 1999;461:107-16
pubmed: 10442170
J Clin Transl Sci. 2017 Apr;1(2):108-114
pubmed: 28649452
J Nurs Scholarsh. 2011 Sep;43(3):274-81
pubmed: 21884373
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD006704
pubmed: 20614448
Cancer Clin Oncol. 2013;2(1):51-61
pubmed: 23935769
Radiother Oncol. 2012 Aug;104(2):205-12
pubmed: 22883107
Brain Behav Immun. 2018 Nov;74:291-295
pubmed: 30217537
J Clin Endocrinol Metab. 1997 Jul;82(7):2182-91
pubmed: 9215292
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Cancer. 2014 Mar 15;120(6):848-54
pubmed: 24338990
Brain Behav Immun. 2016 Feb;52:145-152
pubmed: 26515035
J Clin Oncol. 2008 Feb 20;26(6):971-82
pubmed: 18281672
Int J Behav Med. 2013 Mar;20(1):13-21
pubmed: 21928059
Oncology. 2005;68(4-6):405-13
pubmed: 16020970
Cancer. 2004 Jan 15;100(2):425-32
pubmed: 14716781
Brain Behav Immun. 2010 Aug;24(6):968-74
pubmed: 20353817
Biol Psychiatry. 2008 Aug 15;64(4):266-72
pubmed: 18440494
Brain Behav Immun. 2018 Mar;69:364-373
pubmed: 29269321
Biol Psychiatry. 2004 Apr 1;55(7):745-51
pubmed: 15039004
FEBS Lett. 2000 Dec 29;487(2):229-33
pubmed: 11150515
J Biol Chem. 1998 Nov 6;273(45):29291-4
pubmed: 9792627
Brain Behav Immun. 2018 Mar;69:296-303
pubmed: 29217263